<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124722</url>
  </required_header>
  <id_info>
    <org_study_id>P05798</org_study_id>
    <secondary_id>021049</secondary_id>
    <nct_id>NCT00124722</nct_id>
  </id_info>
  <brief_title>A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia</brief_title>
  <official_title>A Randomized, Assessor-blind, Dose-ranging, Phase IIIB, Multicenter Trial Comparing the Intubating Conditions and Time Course of Block of Three Different Intubating Doses (0.45 mg/kg, 0.6 mg/kg, and 1.0 mg/kg) of Zemuron® in Pediatric and Adolescent Subjects Under General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the time course of muscle relaxation after
      administration of three different single intravenous bolus doses of rocuronium bromide for
      intubation (insertion of a tube through the nose or mouth into the trachea to provide
      artificial ventilation) in term neonates (birth to &lt;28 days old), infants (28 days to &lt;=3
      months) and toddlers (&gt;3 months to &lt;=2 years), children (2 years to less than or equal to 11
      years of age), and adolescents (&gt;11 years to less than or equal to 17 years of age).

      Subjects in each of the age groups will be randomized to one of 3 Zemuron® doses: 0.45 mg/kg,
      0.6 mg/kg, or 1.0 mg/kg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to reappearance of T3 (time from end-administration of Zemuron to reappearance of the third twitch of a TOF stimulation)</measure>
    <time_frame>during surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset time, maximum block, time to reappearance of T1, Recovery to TOF 0.7, 0.8 and 0.9 and intubation score</measure>
    <time_frame>during and after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>0.45 mg/kg Zemuron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.45 mg/kg Zemuron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6 mg/kg Zemuron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.6 mg/kg Zemuron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg/kg Zemuron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg Zemuron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium bromide (Zemuron)</intervention_name>
    <description>A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.</description>
    <arm_group_label>0.45 mg/kg Zemuron</arm_group_label>
    <other_name>ORG 9426</other_name>
    <other_name>SCH 900085</other_name>
    <other_name>Zemuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium bromide (Zemuron)</intervention_name>
    <description>A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.</description>
    <arm_group_label>0.6 mg/kg Zemuron</arm_group_label>
    <other_name>ORG 9426</other_name>
    <other_name>SCH 900085</other_name>
    <other_name>Zemuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium bromide (Zemuron)</intervention_name>
    <description>A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.</description>
    <arm_group_label>1.0 mg/kg Zemuron</arm_group_label>
    <other_name>ORG 9426, SCH 900085, Zemuron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects from birth up to 17 years of age who will be scheduled for
             surgery under general anesthesia.

        Exclusion Criteria:

          -  Subjects whose parent(s) or legal guardian(s) are not willing to give written consent
             and where applicable, subjects who have not given appropriate assent to participate in
             the trial will not be allowed to enter.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Tirotta CF, Brandom B, Siddiqui MS, Ehlers M, Betzel J, Chen J-Y, De Bie J, Blobner M. Time Course of Rocuronium-Induced Neuromuscular Blockade in Pediatric Patients: A Phase III, Randomized, Dose-Response Study. J Anesthe Clin Res. 2012;3:189.</citation>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2005</study_first_submitted>
  <study_first_submitted_qc>July 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2005</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

